loading...| Preferred Name |
Opebacan |
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114296 |
| CAS_Registry |
206254-79-7 |
| code |
C114296 |
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C63923 |
| Contributing_Source |
CTRP FDA |
| DEFINITION |
An injectable formulation composed of opebacan, a 21 kDa recombinant fragment of human bactericidal/permeability-increasing protein (BPI), with potential anti-infective activity. Upon intravenous administration, opebacan is able to mimic BPI and binds to and neutralizes lipopolysaccharides (LPS or endotoxins), which are components of the cell wall of gram-negative bacteria that induce a potent innate immune response. This may prevent an endotoxin-mediated inflammatory response and may prevent graft-versus-host-disease (GvHD) after myeloablative allogeneic hematopoietic stem cell transplantation (aHSCT). BPI, a host-defense protein against microbial infection, is naturally produced by neutrophils. Chemo- and radio-therapy induce neutropenia and depletion of endogenous BPI. These therapies also cause intestinal damage and release of bacterial endotoxins into the bloodstream, which initiate a systemic inflammatory response, activate donor T-lymphocytes and possibly cause GvHD following aHSCT. |
| Display_Name |
Opebacan |
| FDA_UNII_Code |
4X9EPQ6FMA |
| FULL_SYN |
OPEBACAN rBPI- 21 rBPI 21 132-L-Alanine-1-193-bactericidal/Permeability-increasing Protein (Human) Opebacan Recombinant BPI 21 Fragment Neuprex |
| label |
Opebacan |
| NCI_Drug_Dictionary_ID |
758239 |
| NCI_META_CUI |
CL471807 |
| PDQ_Closed_Trial_Search_ID |
758239 |
| PDQ_Open_Trial_Search_ID |
758239 |
| Preferred_Name |
Opebacan |
| prefixIRI |
Thesaurus:C114296 |
| prefLabel |
Opebacan |
| Semantic_Type |
Pharmacologic Substance |
| subClassOf |
| Delete | Mapping To | Ontology | Source |
|---|---|---|---|
| There are currently no mappings for this class. | |||